Novo: CHMP recommends EU approval of FREHEMGO® (denecimig), the first factor VIIIa mimetic offering monthly, once every two weeks and weekly dosing in a pre-filled pen, for the treatment of haemophilia A

Novo’s denecimig demonstrates tolerability after switch from emicizumab in FRONTIER5 study of people with haemophilia A as published in the Journal of Thrombosis and Haemostasis

Novo and Anthropic will collaborate to advance drug discovery with Claude